Revealing Changes in Celecoxib Nanostructured Lipid Carrier's Bioavailability Using Hyaluronic Acid as an Enhancer by HPLC-MS/MS.

Drug design, development and therapy2024Zhu Y, Chen M, Yang C, et al.

Study designOther primary literature

SubjectAnimal

Record checks

Study design: Other primary literature
Subject: Animal
Publication year: 2024
Source: doi.org
Abstract display: Not reproduced here
Publication status: Active
Status checked: 17 Aug 2026
Collected: 4 Aug 2026
Freshness: Current
Review stage: Automated
Record status: Published

How to read this record →

Abstract

cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。

MeSH

Administration, OralAnimalsBiological AvailabilityCelecoxibChromatography, High Pressure LiquidDrug CarriersHyaluronic AcidLipidsLiquid Chromatography-Mass SpectrometryMaleNanostructuresRatsRats, Sprague-DawleyTandem Mass Spectrometry

DOI 10.2147/dddt.s461969

PMID 39100220

View source →